文献速递糖尿病

糖尿病技术进展助力改善囊性纤维化患者生活

Advances in diabetes technology to improve the lives of people with cystic fibrosis.
PubMed 文献 · Diabetologia · 2024-07-12

本文综述持续葡萄糖监测(CGM)与胰岛素输注设备等糖尿病技术在囊性纤维化相关糖尿病(CFRD)中的应用进展。文章总结这些技术如何加深对CFRD的理解、可能辅助筛查与诊断,并有望改善CFRD管理、减轻患者负担。

要点

  • CFRD由胰腺外分泌疾病和纤维化致β细胞功能障碍与破坏,兼具1型和2型糖尿病特征。
  • 糖尿病技术可能特别有益于CFRD患者,因其多系统受累且健康问题复杂。
  • CGM和胰岛素输注设备或有助于理解CFRD、筛查诊断及改善管理。

核心结论

  • 糖尿病技术(如CGM和胰岛素输注设备)在加深CFRD理解、辅助筛查诊断和改善管理方面展现前景,可能减轻这一复杂患者群体的负担。

研究设计与样本

  • 综述,总结糖尿病技术在囊性纤维化相关糖尿病(CFRD)中的应用进展。

主要发现

  • 糖尿病技术增进了对CFRD的理解,包括高血糖如何影响囊性纤维化患者的临床结局。
  • 糖尿病技术可能在CFRD的筛查和诊断中有所帮助。
  • 糖尿病技术有望改善CFRD的管理,并减轻该诊断给本已复杂的患者群体增加的负担。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

People with cystic fibrosis (CF) are at risk for dysglycaemia caused by progressive beta cell dysfunction and destruction due to pancreatic exocrine disease and fibrosis. CF-related diabetes (CFRD) is a unique form of diabetes that has distinctive features from both type 1 and type 2 diabetes. Recent advances in diabetes technology may be of particular benefit in this population given the complex, multi-system organ involvement and challenging health issues that people with CFRD often face. This review summarises how diabetes technologies, such as continuous glucose monitors (CGMs) and insulin delivery devices: (1) have improved our understanding of CFRD, including how hyperglycaemia affects clinical outcomes in people with CF; (2) may be helpful in the screening and diagnosis of CFRD; and (3) offer promise for improving the management of CFRD and easing the burden that this diagnosis can add to an already medically complicated patient population.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Scully KJ, Marks BE, Putman MS, et al. Advances in diabetes technology to improve the lives of people with cystic fibrosis. Diabetologia. 2024. PMID: 38995399. doi:10.1007/s00125-024-06223-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。